102 related articles for article (PubMed ID: 32725633)
1. Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Kang DW; Hwang WC; Noh YN; Park KS; Min DS
J Pathol; 2020 Nov; 252(3):304-316. PubMed ID: 32725633
[TBL] [Abstract][Full Text] [Related]
2. Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling.
Ho KH; Lee YT; Chen PH; Shih CM; Cheng CH; Chen KC
Neurotherapeutics; 2021 Apr; 18(2):1371-1392. PubMed ID: 33410111
[TBL] [Abstract][Full Text] [Related]
3. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Fabro F; Kers TV; Feller KJ; Beerens C; Ntafoulis I; Idbaih A; Verreault M; Connor K; Biswas A; Salvucci M; Prehn JHM; Byrne AT; O'Farrell AC; Lambrechts D; Dilcan G; Lodi F; Arijs I; Kremer A; Tching Chi Yen R; Chien MP; Lamfers MLM; Leenstra S
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958662
[TBL] [Abstract][Full Text] [Related]
4. Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated mechanisms of chemotherapy resistance in glioblastoma.
Xiao W; Wang S; Zhang R; Sohrabi A; Yu Q; Liu S; Ehsanipour A; Liang J; Bierman RD; Nathanson DA; Seidlits SK
Matrix Biol; 2020 Jan; 85-86():128-146. PubMed ID: 31028838
[TBL] [Abstract][Full Text] [Related]
5. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Li J; Kaneda MM; Ma J; Li M; Shepard RM; Patel K; Koga T; Sarver A; Furnari F; Xu B; Dhawan S; Ning J; Zhu H; Wu A; You G; Jiang T; Venteicher AS; Rich JN; Glass CK; Varner JA; Chen CC
Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33846242
[TBL] [Abstract][Full Text] [Related]
6. The Temozolomide-Doxorubicin paradox in Glioblastoma in vitro-in silico preclinical drug-screening.
Oraiopoulou ME; Tzamali E; Psycharakis SE; Tzedakis G; Makatounakis T; Manolitsi K; Drakos E; Vakis AF; Zacharakis G; Papamatheakis J; Sakkalis V
Sci Rep; 2024 Feb; 14(1):3759. PubMed ID: 38355655
[TBL] [Abstract][Full Text] [Related]
7. A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.
Brown JMC; Zaben M; Ormonde C; Sharouf F; Spencer R; Bhatt H; Siebzehnrubl FA; Gray WP
Biochem Pharmacol; 2023 Feb; 208():115410. PubMed ID: 36632958
[TBL] [Abstract][Full Text] [Related]
8. En route to local glioblastoma treatment with temozolomide doped hyaluronan fibres: formulation and
Belhajová M; Vícha A; Burgert L; Brožková I; Michalíčková L; Hrdina R; Moravec T; Netuka D; Musil Z; Hrdina R
RSC Med Chem; 2023 Sep; 14(9):1662-1666. PubMed ID: 37731694
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Metabolic reprogramming for acquiring therapeutic resistance in glioblastoma.
Hsu TI
Front Oncol; 2023; 13():1220063. PubMed ID: 37519794
[No Abstract] [Full Text] [Related]
10. Pharmacological targeting of one‑carbon metabolism as a novel therapeutic strategy for glioblastoma.
Sun Y; Mu G; Xue Z; Li X; Lin X; Han M
J Transl Med; 2023 Jun; 21(1):424. PubMed ID: 37386497
[No Abstract] [Full Text] [Related]
11. Deletion of phospholipase D1 decreases bone mass and increases fat mass via modulation of Runx2, β-catenin-osteoprotegerin, PPAR-γ and C/EBPα signaling axis.
Kang DW; Hwang WC; Noh YN; Che X; Lee SH; Jang Y; Choi KY; Choi JY; Min DS
Biochim Biophys Acta Mol Basis Dis; 2021 May; 1867(5):166084. PubMed ID: 33497821
[TBL] [Abstract][Full Text] [Related]
12. Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma.
Kang DW; Hwang WC; Noh YN; Kang Y; Jang Y; Kim JA; Min DS
J Cell Physiol; 2021 Jan; 236(1):549-560. PubMed ID: 32869317
[TBL] [Abstract][Full Text] [Related]
13. Pleckstrin homology domain of phospholipase D2 is a negative regulator of focal adhesion kinase.
Kim MK; Hwang WC; Min DS
BMB Rep; 2021 Feb; 54(2):112-117. PubMed ID: 32843133
[TBL] [Abstract][Full Text] [Related]
14. TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
Nie E; Jin X; Miao F; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Xie M; You Y
Neuro Oncol; 2021 Mar; 23(3):435-446. PubMed ID: 32813021
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells.
Hwang WC; Kang DW; Kang Y; Jang Y; Kim JA; Min DS
Biol Res; 2020 Oct; 53(1):34. PubMed ID: 32998768
[TBL] [Abstract][Full Text] [Related]
16. Biomaterial-based
Ahmed T
Cancer Pathog Ther; 2023 Jul; 1(3):177-194. PubMed ID: 38327839
[TBL] [Abstract][Full Text] [Related]
17. Phospholipases in Gliomas: Current Knowledge and Future Perspectives from Bench to Bedside.
Marvi MV; Neri I; Evangelisti C; Ramazzotti G; Asioli S; Zoli M; Mazzatenta D; Neri N; Morandi L; Tonon C; Lodi R; Franceschi E; McCubrey JA; Suh PG; Manzoli L; Ratti S
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238668
[TBL] [Abstract][Full Text] [Related]
18. Non-coding RNAs and glioma: Focus on cancer stem cells.
Rajabi A; Kayedi M; Rahimi S; Dashti F; Mirazimi SMA; Homayoonfal M; Mahdian SMA; Hamblin MR; Tamtaji OR; Afrasiabi A; Jafari A; Mirzaei H
Mol Ther Oncolytics; 2022 Dec; 27():100-123. PubMed ID: 36321132
[TBL] [Abstract][Full Text] [Related]
19. mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.
Ramaiah MJ; Kumar KR
Mol Biol Rep; 2021 May; 48(5):4813-4835. PubMed ID: 34132942
[TBL] [Abstract][Full Text] [Related]
20. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Li H; Liu Q; Chen Z; Wu M; Zhang C; Su J; Li Y; Zhang C
Cell Death Dis; 2021 Mar; 12(3):252. PubMed ID: 33674567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
